TY - JOUR
T1 - Nonsense-mediated RNA decay is a unique vulnerability of cancer cells harboring sf3b1 or u2af1 mutations
AU - Cheruiyot, Abigael
AU - Li, Shan
AU - Srivatsan, Sridhar Nonavinkere
AU - Ahmed, Tanzir
AU - Chen, Yuhao
AU - Lemacon, Delphine S.
AU - Li, Ying
AU - Yang, Zheng
AU - Wadugu, Brian A.
AU - Warner, Wayne A.
AU - Pruett-Miller, Shondra M.
AU - Obeng, Esther A.
AU - Link, Daniel C.
AU - He, Dalin
AU - Xiao, Fei
AU - Wang, Xiaowei
AU - Bailis, Julie M.
AU - Walter, Matthew J.
AU - You, Zhongsheng
N1 - Funding Information:
4boxB and lN-V5-UPF3B expression constructs, and to Dr. Sheila Stewart for providing recombinant adenoviruses expressing RNH1. SMG1i was provided by Amgen Inc. The authors thank Drs. Rick Austin and Tim Cushing for leading efforts at Amgen to develop the SMG1 inhibitor used in this study. Support for procurement of human samples was provided by the Genomics of AML Program Project of the NCI (P01 CA101937). This work was supported by an NIH grant (R01GM098535) and Siteman Investment Program Awards (4036, 5124) from Washington University to Z. You., a Developmental Research Program (DRP-1901) of the SPORE in Leukemia (NIH/NCI, P50CA171963) and the Edward P. Evans Foundation to M.J. Walter and
Funding Information:
A. Cheruiyot reports grants from Howard Hughes Medical Institute during the conduct of the study. S. Li reports grants from NIH, Washington University, and grants from Edward P. Evans Foundation during the conduct of the study. T. Ahmed reports grants from NIH, Washington University, Edward P. Evans Foundation, and other support from Howard Hughes Medical Institute during the conduct of the study. Y. Chen reports grants from NIH, Washington University, Edward P. Evans Foundation, and other support from Howard Hughes Medical Institute during the conduct of the study. J.M. Bailis is an employee of and holds stock in Amgen, Inc. Z. You reports grants from NIH, Washington University, Edward P. Evans Foundation, and other support from Howard Hughes Medical Institute during the conduct of the study. The article used the SMG1 inhibitor that was obtained from Amgen under a Research Program Agreement. No financial support was provided by Amgen for this study No disclosures were reported by the other authors.
Publisher Copyright:
© 2021 American Association for Cancer Research Inc.. All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Nonsense-mediated RNA decay (NMD) is recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTC) for degradation, however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system to accurately measure NMD activity in individual cells. A genome-wide CRISPR-Cas9 knockout screen using this reporter system identified novel NMDpromoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, cells with mutations in the spliceosome genes SF3B1 and U2AF1, which are commonly found in myelodysplastic syndrome (MDS) and cancers, have overall attenuated NMD activity. Compared with wild-type (WT) cells, SF3B1- A nd U2AF1-mutant cells were more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage, and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition was rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, these findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel synthetic lethal strategy for the treatment of MDS and cancers with spliceosome mutations.
AB - Nonsense-mediated RNA decay (NMD) is recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTC) for degradation, however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system to accurately measure NMD activity in individual cells. A genome-wide CRISPR-Cas9 knockout screen using this reporter system identified novel NMDpromoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, cells with mutations in the spliceosome genes SF3B1 and U2AF1, which are commonly found in myelodysplastic syndrome (MDS) and cancers, have overall attenuated NMD activity. Compared with wild-type (WT) cells, SF3B1- A nd U2AF1-mutant cells were more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage, and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition was rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, these findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel synthetic lethal strategy for the treatment of MDS and cancers with spliceosome mutations.
UR - http://www.scopus.com/inward/record.url?scp=85114331969&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-4016
DO - 10.1158/0008-5472.CAN-20-4016
M3 - Article
C2 - 34215620
AN - SCOPUS:85114331969
SN - 0008-5472
VL - 81
SP - 4499
EP - 4513
JO - Cancer Research
JF - Cancer Research
IS - 17
ER -